TrueRelief has been shown to reduce opioid usage 50%
TrueRelief is a non-opioid, non-invasive neuromodulation device to manage post-op pain as an alternative to opioids.
Our proprietary electrical configuration combined with our unique probe delivery system make TrueRelief unlike any other electrical therapy.
- 20,000 Hz high frequency (vs. 50-400 Hz for other electrical therapies).
- Pulsed direct current (vs. alternating current).
- Dynamically directed stainless steel tipped probes (vs. static electrodes) administered by trained clinicians.
*TrueRelief is protected by multiple US and foreign patents.
TrueRelief is a non-opioid, non-invasive neuromodulation device to manage post-op pain as an alternative to opioids.
Our proprietary electrical configuration combined with our unique probe delivery system make TrueRelief unlike any other electrical therapy.
- 20,000 Hz high frequency (vs. 50-400 Hz for other electrical therapies).
- Pulsed direct current (vs. alternating current).
- Dynamically directed stainless steel tipped probes (vs. static electrodes) administered by trained clinicians.
*TrueRelief is protected by multiple US and foreign patents.
Most Post-Op TrueRelief protocols call for three 10-minute treatments in the first 48 hours after surgery. Treatments commence in recovery and are nurse or technician administered and non-sterile.
In a recently concluded sham-controlled, 134-subject clinical trial of post-op cesarean section patients, TrueRelief treated patients:
- Consumed significantly lower morphine milligram equivalents prior to discharge (p=0.04).
- Required fewer oxycodone tablets prescribed at discharge (p≤0.01) and more likely to be discharged without opioid prescription (p=0.03).
TrueRelief’s Mechanism of Action was the subject of a two-year study that was published after peer review in 2022.
TrueRelief will conclude a 156-subject, sham-controlled clinical trial using TrueRelief to manage post-op pain for bariatric surgery patients in the Fall of 2023. Primary endpoints will include MME consumption, length of stay, reported pain and patient satisfaction.
Any surgical intervention that typically requires opioids for pain management is a candidate for TrueRelief.
- Spine Surgery
- Joint Replacement
- Colorectal Surgery
“We treat the operative areas immediately after surgery and then for two days post-op. We found that patients who would normally require narcotics, now need zero prescription medication at all. I simply treat my surgical patients with TrueRelief and acetaminophen.
“I might add that I have been on the receiving end of the device. Following my own back surgery, I required no prescription medications post-operatively.”
Harry Glassman, M.D.
Plastic & Reconstructive Surgeon
Beverly Hills, CA
“We treat the operative areas immediately after surgery and then for two days post-op. We found that patients who would normally require narcotics, now need zero prescription medication at all. I simply treat my surgical patients with TrueRelief and acetaminophen.
“I might add that I have been on the receiving end of the device. Following my own back surgery, I required no prescription medications post-operatively.”
Harry Glassman, M.D.
Plastic & Reconstructive Surgeon
Beverly Hills, CA
TrueRelief has been used extensively to treat acute and chronic pain in a clinical setting.
- Back & Neck Pain
- Neuropathy
- Sports Injury Pain
- Ankle, Knee & Shoulder Pain
- Tennis Elbow
- Claudication
- Wound Pain
- Carpel Tunnel
- TMJ
What can you expect with clinical treatments for acute and chronic pain?
Typical treatments in a clinical setting range from 10-20 minutes for most acute injuries or conditions, or 15-25 minutes for more complex chronic conditions.
The number of treatments required varies by condition. Some patients require as few as 1-4 treatments, while others (usually with long standing chronic pain) may require 4-8 treatments.
TrueRelief treatments have a cumulative effect so treatments should generally not be spaced more than every third day and usually every other day is optimal. In some acute cases and some post-surgical cases, initial treatments may be called for every day.
CLINICAL DATA
A physical therapy practice in Charlotte, NC:
- Gave 189 TrueRelief treatments to 54 patients (an average of 3.5 treatments per patient).
- 99% of all treatments generated some level of pain relief, with an average of 57% relief for each treatment.
- After the full course of their treatments (which ranged from one treatment to eleven, varying by patient and condition), 74% of all patients achieved total elimination of their pain.
TrueRelief is only available through healthcare professionals.
TrueRelief is FDA-cleared for relief of chronic intractable pain, and as an adjunctive treatment in the management of post-surgical and post-traumatic acute pain. It is intended for use under the supervision of a Healthcare Professional. TrueRelief should not be used on patients who are pregnant or have a cardiac demand pacemaker. For a complete listing of the Indication for Use and all contraindications, warnings, precautionsand adverse reactions please click here.
Federal grant awarded from the Health & Human Services Department
The TrueRelief technology was awarded a $244,000 federal grant from the Health & Human Services Department, in conjunction with the Treasury Department and the National Institutes of Health.- This Therapeutic Discovery Project Program was initiated by the government to improve healthcare by supporting biotech firms with the largest potential.
- The selection criteria was centered on identifying new technologies that offered significant likelihood to produce new therapies, address unmet medical needs, and reduce the long-term growth of healthcare costs.
About Us
Management Team
Herminio C. Llevat | CEO
Herminio has been an accomplished serial entrepreneur for over 25 years, building successful businesses and brands both from the ground up and through acquisition. He has extensive experience in health, beauty and personal care, building off his earliest roles in brand management at Procter & Gamble following his graduation from Harvard College, and as an electronics market manager at DuPont after completing his MBA from Harvard Business School. As a founding partner in TrueRelief, Herminio is keenly focused on growing enterprise value with particular attention to nurturing long-term strategic partnerships that can generate exponential growth, as well as taking a hands-on role in developing our wearable technology, which likewise offers extraordinary revenue opportunity.
John Crosson | President
John has over 30 years of experience as a marketer building some of the most recognized and valuable brands in the world including BMW, Nestle, Hilton, Gallo, and Harry Potter (for Warner Bros.), and as a CEO led a company generating over $200 million in annual revenue. As the angel investor behind the technology that has become TrueRelief, John took a single patent for a precursor version and worked with numerous clinicians to evolve the technology to where it is today, amassing 15 additional patents in the process (8 as the named inventor), with more than a dozen pending applications, as well as FDA clearance. Additionally, he spent 10 years on the board of the Crohn’s & Colitis Foundation (including three years as its Chair), during which time he oversaw over $350 million in spending on medical research related to these diseases.
Advisors
Timir Datta-Chaudhuri | PhD
Timir Datta-Chaudhuri heads the Bioelectronics Laboratory at the Institute of Bioelectronic Medicine, Feinstein Institutes for Medical Research, which is the research arm of Northwell Health. Dr. Datta-Chaudhuri’s research focuses on the intersection of biology and electronics. His areas of expertise include medical devices, electronics for neuromodulation, neural interface materials, and integrated circuit design. Prior to joining the Feinstein Institutes, Dr. Datta-Chaudhuri oversaw the development of neuromodulation technology at Lawrence Livermore National Laboratory (LLNL) in their collaboration with the Biological Technologies Office at the Defense Advanced Research Projects Agency (DARPA). His current research focuses on the development of next generation bioelectronic therapeutic devices. Dr. Datta-Chaudhuri is a senior member of the Institute of Electrical and Electronics Engineers (IEEE). He has played a key role in Feinstein’s research on TrueRelief and its mechanism of action.
David Hatch Jr | DPM
David Hatch is a practicing podiatrist with a particular emphasis on the critical aspects in the prevention and treatment of the diabetic foot including advanced wound care, re-vascularization, and surgical foot reconstruction. In addition to his clinical practice, Dr. Hatch is a well published researcher of foot and ankle disease and a lecturer and adjunct professor at Midwestern University. Much of Dr. Hatch’s published research is focused on diabetic foot wounds and negative pressure wound therapy. He has also dedicated hundreds of service hours to help others less fortunate including at shelters where he helps address foot and ankle pathology for the needy.
Michael Lavor | MD
A general surgeon by training, Michael Lavor is Medical Director at Saguaro Surgical and The Wound Center in Tucson, Arizona. Dr. Lavor was a member of the Trauma Team at Tucson Medical Center where he also served as Chairman of the Department of Surgery. He is past Chief of Surgery and past Chief of Staff at El Dorado Hospital. Dr. Lavor served in the Navy for twelve years and was Commanding Officer of a Role 2 E in Afghanistan in 2012-13. He worked with Australian Special Forces and Seal Team 4, along with Army, Navy and Marines. He is a board member of BRAVEVets.
Todd Pope
Todd Pope has nearly 30 years of healthcare experience in medical devices, pharmaceutical, and executive management. He is currently the Executive Chairman of Innovators. Prior to this, he was the President and CEO of TransEnterix, the Global President of Johnson & Johnson Cordis, CEO of Liquidia Technologies and President of American Tool Company. He spent 14 years in various management roles with increasing levels of responsibility at both Johnson & Johnson and Boston Scientific. He was named in Time Magazine’s 50 Most Influential People in Healthcare.
Clarence Shields | MD
Clarence Shields has spent most of his career in private practice at the Kerlan-Jobe Orthopaedic Clinic in Los Angeles, during which time he developed the Kerlan-Jobe Sports Medicine Fellowship Program, which has produced more than 220 alumni. He served as team physician for the Los Angeles Rams football team from 1973-1995 and currently serves as medical director for Team Heal (Helping Enrich Athlete’s Lives), a non-profit foundation he created to provide comprehensive medical care, certified athletic trainers, and rehabilitation centers for underserved high school athletes. Dr. Shields has served in multiple capacities for AOSSM, including President in 2001 and as a member of the Board of Directors. He received the Society’s Mr. Sports Medicine award in 2006 and was inducted into the AOSSM’s Hall of Fame in 2011. Dr. Shields has authored more than 50 publications in peer-reviewed journals, multiple chapters in books on sport medicine, as well as the book, Manual of Sports Medicine.
Harry Glassman | MD
Harry Glassman has been practicing plastic surgery in Beverly Hills, California for over 35 years. Dr. Glassman is the author of numerous scientific papers and textbook chapters on the correction of facial aging, eyelid surgery, and breast implantation and implant removal. He has spoken at numerous conferences and appeared on network television news shows for his expertise in plastic and reconstructive surgery. He was an honors graduate of Hahnemann Medical College in Philadelphia. He completed his training as Chief Resident in Plastic and Reconstructive Surgery at UCLA. He furthered his course of study with additional training at the Clinique du Belvedere in Paris, France.
Phillip Horne | MD, PhD
Phillip Horne at Duke University Health System is a spine surgeon. He specializes in minimally invasive strategies, including robotic assisted spinal fusion surgery. Dr. Horne is Board Certified by the American Board of Orthopaedic Surgery. He has authored numerous articles in peer reviewed journals. His current research focus involves robotic spinal surgery and spinal surgery implant technology with goals of optimizing patient outcomes from surgery. Dr. Horne obtained his medical degree and doctorate from The Ohio State University. He completed his Orthopaedic Surgery residency at Duke University and fellowship in spinal surgery at the Hospital for Special Surgery in New York.
Chris Locke
Chris Locke has over 20 years of experience with innovation, research and development within the medical device industry. Chris is currently Vice President, Head of R&D with Vyaire Medical Inc., a leading US respiratory medicine company. Previously, Chris was Chief Innovation Officer with KCI, the largest wound management company prior to its acquisition by 3M in 2020 and the market leader in negative pressure wound therapy (NPWT). He was also Chief Technology Officer with Advanced Medical Solutions Group Plc. Throughout his career, Chris has developed many new products and technologies, principally in the wound care space, and is an inventor on over 380 granted US patents. Chris is based in the U.K. and is a graduate in Computer Sciences from Bournemouth University.
Jonathan Reynolds | PT, PhD
Jonathan Reynolds is Chief Curriculum Officer at Orthology, where he also provides outpatient physical therapy services for musculoskeletal injuries sustained by individuals of all ages, especially industrial workers and performing artists. Dr. Reynolds has over 30 years of experience practicing physical therapy. He holds a PhD in Rehabilitation Science, as well as Bachelor’s and Master’s degrees in Physiotherapy. He served for 4 years in the South African Air Force as an Air Traffic Controller.
Aaron Spitz | MD
Aaron Spitz is a is a top fertility expert, board-certified urologist, and microsurgeon with a broad-based general urology practice. Dr Spitz graduated from Cornell University Medical College. He completed his urology residency at LA County and University of Southern California Medical Center and fellowship at the Baylor College of Medicine. Dr. Spitz has authored several peer reviewed journal articles and chapters regarding treatment for male fertility and is a nationally recognized expert in the treatment of infertility, sexual dysfunction, and hormone replacement in the male. He has lectured to national audiences on these topics. In 2020, the American Urological Association (AUA), presented Dr. Spitz with The Distinguished Service Award.
